INTRODUCTION
Renal transplantation has become the therapy of choice for end-stage renal disease (ESRD), with more than 10,000 renal transplants performed annually in the United States 1 . With appropriate histocompatibility matching and long-term immune suppression most patients now benefit from prolonged graft survival. Prolonged iatrogenic immune suppression (IS), however, carries a substantial risk of both opportunistic infections and secondary malignancies 2 . The intimate connection between IS, opportunistic infections, and secondary malignancies in transplant recipients is highlighted by the development of post-transplant lymphoproliferative disorder (PTLD) following primary infection or reactivation of latent Epstein Barr virus (EBV) infection 3 .
The successful eradication of established disease by the adoptive transfer of EBV-specific autologous cytotoxic T lymphocytes (CTLs) suggests a critical role for endogenous CD8+ T cells in controlling PTLD 4 .
PTLD occurs in 1% to 2% of renal transplant patients 5 . Reported mortality rates range from 50% to 70% and the optimal treatment approach remains highly controversial 6 . Reduction of IS, with or without antiviral drugs, is initially attempted in almost all patients and is reported to result in regression of PTLD lesions in 23% to 50% of patients [7] [8] [9] (reviewed in 10 ). Durable complete responses with this approach, however, are considered rare. The inconsistent response to IS reduction likely reflects the heterogeneity in the type and intensity of IS, the EBV status of the PTLD, the presence of monoclonal vs. polyclonal disease, and other tumor-and host-related factors yet to be defined. To our knowledge, studies assessing both the clinical and immunological response to IS reduction and antiviral drugs as the sole initial intervention for PTLD following renal transplantation in the absence of chemotherapy or biologic therapy are lacking. Cytotoxic chemotherapy, usually reserved for patients who do not respond to IS only.
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Drugs that target EBV replication, such as acyclovir, ganciclovir and foscarnet, have occasionally been associated with objective responses when given alone 13 , and are often used as an adjunct to IS reduction 10 . The efficacy of anti-viral drugs, however, appears to be limited 14 .
Moreover, due to the inconsistent detection of lytic EBV gene products in PTLD 15, 16 , it is often argued that the biological rationale for the use of antiviral drugs in this disease is weak.
Promising preliminary results have been obtained with anti-B-cell monoclonal antibodies in the treatment of PTLD after solid organ transplantation 17, 18 , and with the adoptive transfer of EBVspecific autologous cytotoxic T lymphocytes (CTLs) in bone marrow transplantation-related PTLD 19 . More recently, a new and interesting therapeutic approach has been proposed that is based on the systemic administration of arginine butyrate, which induces the expression of the EBV-encoded viral thymidine kinase (vTK), followed by ganciclovir 20 . The clinical value of this approach, however, remains to be confirmed. We present here a prospective evaluation of the clinical responses and of the immunomodulatory effects achieved with a limited intervention of IS reduction and acyclovir therapy in 11 consecutive renal transplant patients with EBVpositive PTLD.
only.
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MATERIALS AND METHODS
Patients and treatment of PTLD -Eleven consecutive cases of EBV-positive PTLD following kidney (ten) or kidney-pancreas (one) transplantation diagnosed at The Ohio State University Medical Center (OSUMC) between 1997 and 1999 are included in this study. These patients were not enrolled in a clinical trial. Rather, they were treated prospectively with a standardized and uniform approach based on the recommended initial therapy for PTLD, as recently published Consensus Development Meeting on EBV-induced PTLD 10 . Prior to our current study, the dose and schedule of antiviral therapy and the specific schedule of IS reduction was highly variable.
While each patient signed an IRB-approved consent for blood collection and procurement, three patients (patients 2, 3, and 5) did not have a baseline absolute lymphocyte count performed and were therefore not fully evaluable for immunologic correlates. All tumors were EBV-positive diffuse large B-cell lymphomas (DLBCL). Following transplantation, IS consisted of cyclosporin-A (CyA; dosed to target serum levels and toxicity), prednisone, and either azathioprine (150-200 mg/day) or mycophenolate mofetil (MMF; 2-3 gm/day). Following diagnosis of PTLD, azathioprine or MMF was discontinued, CyA was reduced by 50%, and prednisone was rapidly reduced to 5-10 mg daily. Patients were simultaneously started on highdose intravenous acyclovir (ACV, 10 mg/kg IV q 8 hrs) for 4 weeks, followed by maintenance oral ACV (800 mg TID) for 12 months. Diagnostic tests included CT scans of the chest, abdomen, and pelvis, gallium-67 SPECT scan, bone marrow aspirate and biopsy, and evaluation of liver and kidney function and serum LDH. Evaluation of disease response was performed 4-8 weeks after reduction of IS. When possible, repeat biopsies were performed. Complete response only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From (CR) was defined as the disappearance of all lesions present on CT scan, the lack of detectable disease upon rebiopsy, and/or the resolution of all gallium-avid lesions on SPECT scan. The progression-free survival (PFS) was the time from the day IS was first reduced to the time of relapse, death or last follow up. The overall survival (OS) was the time from the day IS was first reduced to the time of death.
In-situ reverse-transcription PCR (IS-RT-PCR) -IS-RT-PCR was performed as previously described 21, 22 . Forward and reverse primers for EBV thymidine kinase were 5'-GAACCCGCATGCTCTCCTT-3' and 5'-TCTGGATGATGCCCAAGACA-3', respectively.
The primers employed for heavy and light chain mRNA analysis and the criteria used to define clonality have been described elsewhere 23 . For each specific mRNA, primers were used as a T cell subset analysis and tetramer assay -T-cell subsets were assessed on fresh blood samples by standard 3-color flow cytometry. EBV-reactive CD8 + T cells were detected by flow cytometry using HLA-B8 tetramers complexed with immunodominant EBV peptides derived from the latent gene, EBNA-3A (FLRGRAYGL), or the immediate early lytic gene, BZLF-1 (RAKFKQLL) 24 . Frozen patient PBMCs were viably thawed, incubated overnight at 37°C, then Statistical analysis -Non-parametric procedures were performed. The Wilcoxon sign rank test was used to assess the change in CD8+ T-cell counts before and after IS reduction 25 .
RESULTS
Patients -Clinical data are summarized in Table 1 . Median age was 45 years (range 24-77).
The median time from transplant to development of PTLD was 16 months (range 8-94 months).
In eight patients (73%) PTLD was diagnosed more than one year after transplant. In three patients both nodal and extranodal sites were involved, and in five patients the kidney allograft was the predominant site of disease. One patient had histologically-proven PTLD of the bladder without an obvious mass. Gallium-67 SPECT scans demonstrated gallium-avid disease in 10 of 11 patients. One patient had histologically-proven PTLD of the liver that was gallium-negative. Figure 1 ). In five of these eight patients, additional tumor sampling during response allowed a serial analysis of clonality and EBV gene expression. In four of the five cases, different B-cell clones were demonstrated after IS reduction (Table 2 ). In addition, there was variation in the number of tumor cells expressing vTK mRNA among different clones from the same patient (Table 2 ). acyclovir are shown in Figure 2 . The progression free survival (PFS) and overall survival (OS) are presented in Figure 3 . Overall, the median time to achieve CR following the initiation of IS For (Figure 4) . In three patients IS reduction was initiated without a baseline CD8+ T cell count (patients 2, 3 and 5); these patients are therefore excluded -14 - from this analysis. All eight patients for whom data are available initially had low numbers of CD3+ T cells ( Figure 4A ) and CD3+CD8+ T cells ( Figure 4B ) at baseline while on IS. All eight patients experienced a significant increase in the number of CD3+CD8+ T cells following IS reduction ( Figure 4B, p=0.0078) . The CD3+CD8+ T cell expansion ranged from 2.5-fold (patient 11) to 32.8-fold (patient 4), and was sustained at the time of last follow up in all but two patients (patient 6 and 7), one of whom relapsed (patient 6), as discussed above. The 
DISCUSSION
To our knowledge, this is the first prospective clinical and immunological analysis of a therapeutic intervention limited to reduction of IS plus antiviral drugs in renal transplant patients with PTLD. We believe that the observations presented in this study provide several novel leads that may improve our understanding of the mechanisms underlying the development and the immune clearance of PTLD. With a median follow-up of 29 months, the observed 82% progression free survival ( Figure 3A ) and 91% overall survival ( Figure 3B ) compare very favorably to those described in previous studies of patients with clonal and late-occurring PTLD treated with cytotoxic chemotherapy 12 or with anti-B-cell mAbs 17, 18 . Previous reports of the treatment of PTLD in renal transplant patients have included reduction of IS and antiviral therapy, but in all of these studies a substantial fraction of patients were treated with other modalities 26, 27 . Therefore the contribution of immune restoration and/or antiviral drugs to the clinical outcome could not be clearly elucidated. In contrast, the present study provides strong evidence that immune restoration and antiviral therapy are highly effective and produce a very high clinical complete response rate in monoclonal and late-occurring PTLD, without additional therapy.
The PTLD patients who experienced a sustained increase in the absolute number of CD3+CD8+ T cells underwent a complete and durable clinical response. This may not be dissimilar to the ability of CD3+CD4+ T cell counts to predict clinical outcome in HIV-infected patients 28 . The emergence and expansion of oligoclonal CD3+CD8+ T cells during regression of PTLD has been previously described in an allogeneic bone marrow transplant patient who had a dramatic complete response following IS withdrawal 29 . In that report, the expanded CD3+CD8+
T-cells displayed MHC class I-restricted cytotoxic activity against autologous EBV+ We have shown in this study that a lytic rather than a latent EBV peptide was a predominant target for the expanded CD3+CD8+ T cells in two responding PTLD patients. It has been generally accepted that PTLD represents a type III latent EBV infection, characterized by the expression of EBNAs 1-6, and LMPs 1 and 2 30 . It was therefore logical to think that the immunodominant target antigens for EBV-specific CTLs in this disease would be derived from this group. Recently, a heterogeneity in EBV latent gene expression has been documented in PTLD lesions, with more restricted patterns of gene expression seen in some patients [31] [32] [33] [34] . In addition, it has become clear that there is often heterogeneity of viral gene expression within a single PTLD lesion [32] [33] [34] . The expression of EBV lytic gene products has been detected in PTLD 33, 34 , but the proportion of cells found to be entering into the lytic cycle has typically been small, and the relevance of EBV replication to the pathogenesis of PTLD has remained obscure 35 . Here we provide direct evidence of the lytic EBV gene vTK (BXLF-1) mRNA expression in all 8 PTLD tumors examined. Importantly we also provide evidence that, in parallel with the clearance of the PTLD, a population of CD8+ T-cells specific for the lytic antigen BZLF-1 expands several-fold following reduction of IS. These data suggest that control of an ongoing EBV lytic cycle may be important not only for resolution of primary EBV infection 36 and prevention of reactivation 37 but also for immune clearance of PTLD. To our knowledge, this report provides the first evidence of a CD8+ T-cell response to the immunodominant lytic gene peptide RAK in PTLD, suggesting an important role for the BZLF-1 antigen both in the pathogenesis of PTLD and in virus-host interaction.
In addition to vTK 38 , another EBV-encoded protein kinase, BGLF-4 39 , is often expressed during early lytic infection. While we have not performed a detailed analysis of BGLF-4 mRNA expression in PTLD, both the vTK and the BGLF-4 gene products have been detected in EBVonly.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From positive lymphoblasts during early lytic infection 40 . While EBV vTK has been shown to have a narrow substrate specificity, selectively phosphorylating only thymidine nucleoside analogues (5-BrdU and AZT) 41 , BGLF-4 is assumed to have the capacity to phosphorylate guanosine analogues (acyclovir, ganciclovir), although this has not been formally demonstrated 40 . It is tempting to speculate that the presence of both gene products in PTLD might facilitate the selective targeting of actively replicating or reactivated EBV-positive B-cells with combination antiviral therapy 42, 43 . A more complete characterization of the coexpression of vTK and BGLF-4 gene products in PTLD is likely required before the use of multiple antiviral agents for prophylaxis and/or treatment of PTLD could be broadly advocated. rejection. The data presented in our study are a step forward in this direction as they suggest a greater importance of lytic viral activity in PTLD than was previously recognized.
In the last few years several additional treatment modalities have emerged for PTLD, adding further complexity to an already difficult management decision. The anti -CD20 mAb rituximab has shown significant activity in PTLD, with response rates averaging 50-60% 18 only.
